Competition Grows In Claudin18.2 As AstraZeneca Seals Antibody Conjugate Deal
Chasing Astellas In Gastric Cancer
Already a major player in the field thanks to Enhertu, AstraZeneca is doubling down in gastric cancer with the new antibody-drug conjugate deal with China’s KYM Biosciences.
You may also be interested in...
To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.
While Astellas is closing in on the first Claudin18.2 antibody therapy cancer approval, CARsgen and Moderna aim to boost responses from a CAR-T approach.
Astellas says its first approval filing globally for zolbetuximab - in Japan for gastric cancer - came faster than expected, as Scrip takes a look at the latest status of other CLDN18.2-targeting candidates in late clinical trials.